• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Talwar on drug program’s impact on urologic medications


“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.

In this video, Ruchika Talwar, MD, shares the take-home message from the recent Journal of Urology paper, “Urologic Drug Price Stewardship – Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.” Talwar is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.

Related Videos
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Diverse doctors having a conversation |  Image Credit: © Flamingo Images - stock.adobe.com
David I. Lee, MD, FACS, answers a question during a video interview
Devon M. Langston, MD, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.